Oxford BioMedica reiterates FY2026 guidance By Investing.com

Oxford BioMedica reaffirmed FY-2026 revenue guidance of £220-240m (60% contracted, >80% including risk-adjusted pipeline) and expects ~10% EBITDA margin with technology-transfer costs driving a first-half EBITDA loss; capex for 2026-27 reduced to ~£50m after a US Durham facility acquisition. FY-2025 net revenue rose to £168.7m (+31% reported, +33% at constant FX) with reported EBITDA £2.3m (including a £9.9m one-off US site gain) and cash of £96.9m; order intake rose 20% to £224m and order book +36% to £204m, pipeline $597m. RBC maintains Outperform with a 1,170p PT (share price 606p), and the company expects 25-30% revenue growth in 2027-28 and EBITDA margin >20% in 2027, supporting a constructive medium-term outlook despite near-term transfer costs.

Analysis

Oxford BioMedica’s recent messaging shifts the center of gravity from growth uncertainty to execution risk: the market is being asked to price material margin expansion that is largely contingent on successful, low-friction technology transfers and US capacity ramp. Those transfers are a common choke point — delays or qualification rework typically compress near-term margins for 6–12 months while consuming OPEX and CRO/CDMO cycles.

A capital‑efficient U.S. footprint materially changes the competitive map for gene therapy CDMO work — it removes a soft barrier for U.S.-based biotech clients who prize local supply and regulatory proximity, and it increases strategic optionality (tolling, co-manufacture, or boutique M&A). That same footprint elevates the company into direct competition with large, diversified CDMOs where price and service bundling can pressure mid-cycle utilization and margins.

Second-order supply effects are underappreciated: the jump in procurement services activity suggests clients are building launch inventories and validation lots, which improves short-term visibility but raises the risk of a revenue mismatch if launch timing slips. Finally, the path to the touted high-margin steady-state requires sequential wins on client transfers and commercial throughput — a binary series of execution checkpoints over the next 12–36 months that will dominate returns more than headline guidance alone.

Key Decisions for Investors

• Long OXB.L via a 24–36 month call spread (size 1–2% NAV). Rationale: convex exposure to multi-year margin re-rating while capping premium outlay. Entry: within the next 4–8 weeks to capture any near-term softening; target exit on a 50–80% realized gain or failure to convert two consecutive tech‑transfer milestones. Risk management: hard stop at 20% of premium.
• Paired trade: long OXB.L (0.75% NAV) / short CTLT (0.75% NAV) for 6–18 months. Rationale: isolate gene‑therapy CDMO execution upside versus exposure to broad CDMO demand cycles; this hedges macro manufacturing pullbacks. Expected R/R: asymmetry if niche capabilities win commercial slots; exit/trim on divergent QoQ order conversion rates or if CTLT outperforms by >15%.
• Buy short-dated protective puts on OXB.L (3–6 month) sized to cover existing equity exposure (cost <0.5% NAV). Rationale: cheap insurance against near-term technology‑transfer setbacks or client launch delays that would cause sharp re-rating. Use puts as tactical hedge around upcoming qualification milestones; roll only if cost remains <2% of position value.
• Prepare an M&A playbook: set alerts for any one-off disposals, partnership announcements, or large-client wins. If an acquiror-like strategic buyer shows interest, look to increase exposure to 2–3% NAV for a decisive 3–6 month event; conversely, trim into any >25% post-announcement pop given concentrated execution tail risks.